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Abstract
Background: Recombinant proteins and in particular single domains or peptides are often poorly immunogenic unless
conjugated to a carrier protein. Virus-like-particles are a very efficient means to confer high immunogenicity to antigens. We
report here the development of virus-like-particles (VLPs) derived from the RNA bacteriophage AP205 for epitope-based
vaccines.
Methodology/Principal Findings: Peptides of angiotensin II, S.typhi outer membrane protein (D2), CXCR4 receptor, HIV1
Nef, gonadotropin releasing hormone (GnRH), Influenza A M2-protein were fused to either N- or C-terminus of AP205 coat
protein. The A205-peptide fusions assembled into VLPs, and peptides displayed on the VLP were highly immunogenic in
mice. GnRH fused to the C-terminus of AP205 induced a strong antibody response that inhibited GnRH function in vivo.
Exposure of the M2-protein peptide at the N-terminus of AP205 resulted in a strong M2-specific antibody response upon
immunization, protecting 100% of mice from a lethal influenza infection.
Conclusions/Significance: AP205 VLPs are therefore a very efficient and new vaccine system, suitable for complex and long
epitopes, of up to at least 55 amino acid residues in length. AP205 VLPs confer a high immunogenicity to displayed
epitopes, as shown by inhibition of endogenous GnRH and protective immunity against influenza infection.
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Introduction
Vaccination has been one of the most effective ways to control
pathogens and prevent disease in the history of medicine.
Essentially all successful prophylactic vaccines work by inducing
neutralizing or protective antibodies against pathogens (polio,
small pox, tetanus) [1–3]. The first attempts to vaccinate were
dominated by live vaccines as e.g., vaccinating against small pox
using first small pox virus itself followed by vaccinia virus. A
constant search for safer vaccines has led to the development of
live attenuated (e.g. Polio Sabin), inactivated (e.g. Polio Salk) and
finally recombinant vaccines based for example on subunits of
viral surface proteins (e.g. HBV and HPV vaccine) [2,4,5].
Regulatory authorities and also public opinion ask for ever safer
and better characterized vaccines [6]. In this respect, the use of a
small portion of an antigen, such as an epitope, instead of full-
length proteins represents a potentially safer vaccine, since it limits
the scope of potential cross-reactivity and concentrates the
antibody response against the desired portion of an antigen. This
is particularly advantageous when targeting self-antigens, as is the
case for immunotherapeutics, which represent a new promising
class of vaccines developed to treat chronic diseases [7–9].
Many epitopes are short peptides, which immunogenicity is low
unless conjugated to a carrier protein. Currently, there is a limited
set of carrier proteins used to generate most of such conjugate
vaccines. One of them is the ubiquitously used Keyhole limpet
hemocyanin (KLH), and two other carrier proteins are toxoids
which are themselves component of other vaccines, Tetanus
toxoid (tetanus vaccine) or Diptheria toxoid (diphteria vaccine).
Due to the complexity of conjugate vaccine formation, which
requires production of the carrier protein, epitopes as well as
chemical conjugation, the cost of goods may sometimes be
prohibitive [8]. A simpler mean to produce such conjugate
vaccines may be to genetically rather than chemically link the
peptide epitopes to the carrier protein. However, the insertion of
epitopes into carrier proteins and in particular virus-like particles
(VLPs), remains fairly unpredictable despite some remarkable
successes [10–13]. Major limitations include accessibility of the
epitope, size limitations, perturbation of the structure of the viral
protein by the inserted epitope, and enforcement of a non-native
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major challenges for regulatory approval due to infectivity or
presence of DNA and resistance genes.
Recently, we have described new vaccines based on a VLP
derived from the RNA bacteriophage Qb, made from 180
subunits assembling into an icosahedral capsid in E. coli. Epitopes
conjugated chemically to these VLPs are displayed in a highly
repetitive and organized manner, inducing strong immune
responses in all species tested [14]. Remarkably, the highly
repetitive display allows to elicit strong antibody responses even
against self-antigens [15–20]. Indeed, vaccines based on epitopes
coupled to Qb have shown clinical efficacy in smoking cessation
and the treatment of hypertension [21–24].
In this report, we describe a new RNA phage based VLP-
vaccine carrier allowing both N- or C-terminal fusion of epitopes.
The VLP is formed from 180 copies of the coat protein. We show
that long (up to at least 55 amino acids) or complex epitopes
(containing multiple cysteine residues) can be fused to this AP205-
derived VLP-carrier. One vaccine successfully induced antibodies
against GnRH, a self-antigen involved in fertility and prostate
cancer. A second epitope fused to AP205 VLPs was the
extracellular domain of the Influenza A M2 protein. Vaccination
of mice with M2-AP205 resulted in 100% protection from lethal
infection with influenza virus.
Results
AP205 has been recently identified as a new RNA bacterio-
phage infecting the Gram-negative bacteria Acinetobacter sp.
Sequence alignment of its coat protein with other RNA phage
coat proteins is difficult since only 5 amino acids (aa) are conserved
among all RNA phages isolated so far, even when using structural
information [25,26]. The N- and C-termini of RNA bacteriophage
coat proteins come close together at the three-fold axis of their
icosahedral shell and are often involved in interactions with each
other, or shielded from the surface. We generated four AP205
genes, allowing rapid insertion of oligonucleotides or genes
encoding a desired epitope to both the N- and C-terminus of
AP205 coat protein, using either a short (3 or 4) or long (8 or 11)
aa spacer to ensure optimal display of the epitope (Fig. 1). Whilst
the shorter spacers were combinations of G and S residues, the
long spacer sequences used were modifications of a linker sequence
present in the so called A1 extension of Qb coat protein [27].
Table 1 presents a list of epitopes vs. VLP vector and spacer
variants used for the construction of model vaccines. In a first set
of experiments, a short peptide, angiotensin II (Ang II), was fused
to the N- and C-terminus of the coat protein, using all four vectors.
The resulting fusion proteins were expressed in E. coli, and
spontaneously assembled into VLPs as detected by electron
microscopy (Fig. 2). VLPs were purified by gel filtration and
tested by Coomassie staining after LDS-PAGE (Fig. 3a). Western
blot analysis of the fused proteins using an antiserum against
AP205 (Fig. 3b) or Ang II (Fig. 3c) confirmed presence of the
angiotensin peptide. In the absence of a crystal structure of AP205
VLP (Tars et al., in progress), the accessibility of epitopes fused at
any one of the coat protein termini can only be tested
experimentally. To this end, we assessed the ability of the various
AP205 VLPs displaying Ang II to inhibit binding of an Ang II-
specific antiserum to an Ang II-conjugate coated on an ELISA
plate (Fig. 4a and b). VLPs were preincubated with the antiserum
specific for Ang II and remaining free antibodies were detected by
ELISA. As seen in Fig. 4a and 4b, both the VLPs with Ang II
fused to the C-terminus, or the N-terminus of AP205 coat protein,
inhibited binding of the anti-Ang II antiserum. Wild type AP205
VLP did not inhibit antibody binding, confirming the specificity of
the inhibition and thereby the accessibility of the peptides on the
surface of the VLPs.
The display of the fused epitopes on the surface of the AP205-
VLP would predict that these epitopes should be highly
immunogenic. In order to test immunogenicity and at the same
Figure 1. Schematic representation of the four AP205 coat
protein fusion constructs. Genes encoding an epitope to be
introduced at the N-terminus of AP205 using a short spacer (in plasmid
pAP378) or a long spacer (in plasmid pAP382) are cloned as NcoI-Kpn2I
cassettes, while for introduction of epitopes to the C-terminus of AP205
coat protein using a short spacer (in plasmid pAP409) or a long spacer
(in plasmid pAP405) a Kpn2I- Mph1103I cassette is used. AP205 cp
stands for AP205 coat protein sequence.
doi:10.1371/journal.pone.0009809.g001
Table 1. Epitopes and AP205 VLPs referred to in the manuscript.
Epitope C-terminal fusions N-terminal fusions
Designation Source Length, aa short linker long linker short linker long linker
Ang II Angiotensin II, aa 1–8 8 + + + +
D2 S.typhi outer membrane protein, aa 266–280 15 + + + +
CXCR4 CXCR4, N-terminal extracellular part, aa 1–39 39 22+ 2
Nef55 HIV Nef, aa 66–100, 132–151 55 2 + 22
GnRH Gonadotropin releasing hormone, aa 1–10 10 2 + 22
M2 M2, N-terminal ectodomain, aa 2–24 24 22 2 + 2
AP205 VLPs are designated by the linker used to fuse the corresponding epitope. Combinations described in the manuscript are referred to with a ‘‘+’’.
doi:10.1371/journal.pone.0009809.t001
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epitopes larger than the 8 aa peptide Ang II, we fused a sequence
encoding the Salmonella typhi outer membrane protein derived
15 aa peptide D2 [28] to AP205 coat protein, using our four
vectors. The resulting coat proteins were expressed in E.coli and
the VLPs purified. All four coat-protein fusions assembled into
VLPs, as was tested by size exclusion chromatography (not shown)
and electron microscopy (Fig. S1). After purification of chimeric
AP205-D2 VLPs by gel filtration to reliable purity confirmed by
LDS-PAGE (Fig. S2), competitive ELISA showed that the D2
peptides are displayed on the outer VLP surface to the same extent
as the Ang II peptide in the corresponding VLPs (not shown). In
order to further test accessibility of the peptide on the VLP and to
test the immunogenicity of the particles, we immunized Balb/c
mice at fortnightly interval with 25 mg of D2-VLPs in the absence
of adjuvant. As shown in Fig. 5, all 4 VLPs were highly
immunogenic, and a robust titer was measured after two
injections. The response is specific for the D2 peptide, as AP205
linked to a control peptide induces antibodies that do not bind to
D2 (data not shown). Display of the D2 peptide with a long linker
at the N-terminus of AP205 VLP seemed, however, to yield less
immunogenic VLPs than using a short linker at the N-terminus, or
displaying the peptide at the C-terminus of the VLP carrier. These
data independently confirm the accessibility of fused epitopes on
the surface of AP205 VLP.
In order to investigate whether peptides of greater length can be
displayed on AP205 VLP, we fused the N-terminal 39 aa
extracellular part of CXCR4 to the N-terminus, and a 55 aa
HIV polyepitope containing Nef consensus T-cell epitopes to the
C-terminus of AP205 VLP. Both fusion coat proteins assembled
into VLPs and displayed their epitopes, as was confirmed by
electron microscopy (Fig. S3), SDS-PAGE and Western blot (not
shown). Thus, peptides as large as 55 aa in length can be fused to
AP205 VLP.
We wanted next to see whether the high immunogenicity of the
AP205-VLP vaccines could generate antibodies neutralizing their
target and having a useful therapeutic effect in vivo. To this end, we
selected GnRH as a target for neutralisation in mice. This
provided additionally the opportunity to test whether AP205 VLP
based vaccines could break B cell unresponsiveness towards self-
Figure 2. Electron micrographs of negatively stained AP205-Ang II VLPs. AP205 VLPs displaying the Ang II peptide fused to the C-terminus
(AP441 – short linker, AP442 – long linker), or the N-terminus (AP446 – short linker, AP447 – long linker) of AP205 coat protein.
doi:10.1371/journal.pone.0009809.g002
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currently targeted for immunotherapy are self-antigens. Anti-
bodies neutralising GnRH have the potential to act as androgen-
deprivation therapy used to date to treat prostate cancer
[29–31], since prostate cancer cells depend on testosterone for
growth [32]. Fertility management may be an additional potential
use of such a vaccine [33]. Therapeutically meaningful induc-
tion of neutralising antibodies against GnRH should lead to a
decrease in LH and FSH production and subsequently to reduced
levels of androstenone and gonadal steroids like estrogens and
testosterone. This in turn will cause testis atrophy that can be
monitored as testis weight reduction.
We therefore fused murine GnRH to the C-terminus of AP205
coat protein, using a long spacer. The fused coat protein
assembled to VLPs in E. coli as determined by electron
microscopy of purified VLPs. Presence of the peptide in AP205-
VLPs was confirmed by western blot. Male adult mice were
immunized once at 9 weeks of age with 50 mg of AP205-GnRH
and boosted three weeks later with the same dose. Neutralization
of GnRH activity was assessed by measuring testis weight 70 days
after initial immunisation. As seen in Fig. 6a, immunisation with
AP205-GnRH led to a 38% decrease in testis weight (p=0.003, t-
test), demonstrating the neutralization activity of raised antibodies.
Antibody titers and testosterone levels were monitored on day 0,
21, 28, 45 and 70. A high antibody titer was already achieved after
the first immunisation in all animals on day 21, and was further
boosted after the second injection (Fig. 6b), further confirming that
Figure 3. AP205-Ang II VLPs analyzed by dodecyl sulphate
PAGE and Western blot. After purification by gel filtration, AP205
VLPs carrying Ang II peptide fused to the C-terminus (AP441 and AP442)
or N-terminus (AP446 and AP447) of AP205 coat protein were heated at
95uC in sample buffer for 5 minutes prior to loading. (a) Coomassie-
stained LDS-PAGE of corresponding chimeric proteins; (b) Western blot
with an AP205 coat protein-specific rabbit serum; (c) Western blot with
an Ang II-specific mouse serum. The migration of all four AP205 coat
proteins carrying Ang II is retarded in comparison to wt AP205 coat
protein (130 aa). Accordingly, migration of coat protein fused to AP205
coat protein using a long spacer (AP442 and AP447) is slower than the
migration of coat proteins containing a short spacer (AP441 and
AP446).
doi:10.1371/journal.pone.0009809.g003
Figure 4. Display of Ang II on AP205 VLP assessed by inhibition
ELISA. Ang II was conjugated to RNAse, and coated on ELISA plates.
The anti-Ang II serum was pre-incubated with serial dilutions of the 4
VLPs displaying Ang II or wt AP205, and subsequently added to the
wells coated with RNAse-Ang II. Signals shown on the Figure are
normalized and are given as % binding. The VLP concentration [mg/ml]
was log transformed. (a) VLPs displaying Ang II at the C-terminus of
AP205 coat protein using a short (AP441) or long spacer (AP442) or wt
AP205 VLP (AP205). (b) VLPs displaying Ang II at the N-terminus of
AP205 coat protein using a short (AP446) or long spacer (AP447) or wt
AP205 VLP (AP205).
doi:10.1371/journal.pone.0009809.g004
VLP for Epitope Vaccines
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9809the immunisation had efficiently overcome B-cell unresponsive-
ness. The response against GnRH is specific, as antibodies
generated against AP205 alone do not recognize GnRH (data
not shown). As expected, GnRH neutralization led to a decrease in
testosterone levels, and we observed a reduction in testosterone
starting from day 28, coincidentally with reaching high antibody
titers after the booster immunisation (Fig. 6, b and c). The median
of the testosterone level, averaged between day 28 and 70, was
81% lower in the AP205-GnRH treated animals when compared
to untreated animals (p=0.008, Mann-Whitney test).
The experiments above demonstrate that AP205 VLP induced
rapidly a high antibody response in all animals after a single
injection. This is particularly advantageous in cases where a rapid
immune response has to be mounted against a pathogen, for
example in the case of an influenza pandemic. Currently,
influenza vaccines contain as antigens hemagglutinin and
neuraminidase from three strains selected every year by the
WHO. Use of a conserved antigen not subject to yearly variation
would be a considerable improvement. The N-terminal M2
epitope of influenza is such a conserved epitope [34–36].
Antibodies raised against M2 do not neutralise influenza virions,
but rather act through antibody dependent cytotoxicity (ADCC) to
limit and clear viral infection [35]. In order to test whether an
AP205 VLP based vaccine may elicit a high enough antibody
responses to protect against influenza virus-infection, we fused the
N-terminal ectodomain of Influenza A M2 protein to the N-
terminus of AP205 VLP using a short spacer. The coat proteins
fused to M2 assembled into VLPs, as was assessed by electron
microscopy. The protective effect of the M2-AP205 VLPs against
a challenge with the influenza PR 8 strain was assessed in C57BL/
6 mice. The animals were immunized twice with M2-AP205 or
AP205 only, and challenged intranasally (i.n.) 13 days after the last
injection with a lethal dose of influenza virus. The mice mounted a
strong immune response against M2 as well as against AP205
already after the first injection, and this response was boosted after
the second injection (Fig. 7a). The mice immunized with control
AP205 produced high antibody titers against AP205 but not
against M2. All mice immunized with M2-AP205 were protected
against the influenza challenge, while for the control group, all
mice succumbed to the lethal infection (Fig. 7b). While control
animals experienced severe weight and temperature loss M2-
AP205 vaccinated animals were largely protected from symptoms
of disease.
Figure 5. Immunogenicity of D2 peptide displayed on AP205
VLPs. AP205 VLPs with the D2 peptide fused to the C-terminus (AP418,
short linker, and AP420, long linker) and to the N-terminus (AP421, short
linker, and AP422, long linker) were injected s.c. at a dose of 25 mg
twice, on day 0 and 14. Sera were collected on day 21, and IgG titre
measured by ELISA. Pre-immune titre was too low to be determined,
and was arbitrarily attributed the value of 1:100, the lowest dilution of
serum used in the assay.
doi:10.1371/journal.pone.0009809.g005
Figure 6. Inhibition of GnRH function in mice immunized with
AP205-GnRH. (a) Testis weight in male C57BL/6 mice immunized with
50 mg AP205 GnRH, or untreated, on day 0 and 21. Mice were sacrificed
on day 70. There was a 38% decrease in testis weight in the AP205-
GnRH group compared to the untreated control group (p=0.003, t-
test). (b) Anti-GnRH IgG antibody titre measured by ELISA. The mice
were immunized on day 0, and 21 with 50 mg AP205-GnRH, and anti-
GnRH ELISA titres measured on day 21, 28, 45, and 70. (c) Testosterone
level measurements. Testosterone levels were measured by ELISA in
sera collected on day 0, 21, 28, 45 and 70. Error bars are the standard
error of the mean. The median of the testosterone level, averaged
between day 28 and 70, was 81% lower in the AP205-GnRH treated
animals when compared to untreated animals (p=0.008, Mann-Whitney
test).
doi:10.1371/journal.pone.0009809.g006
VLP for Epitope Vaccines
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VLPs are very potent inducers of antibody responses not only
against themselves but also against essentially any antigen
displayed on them. Here we describe a new RNA-phage derived
VLP that allows genetic fusion of peptide epitopes for display on
their surface. Using various antigens, including a self-peptide, we
demonstrate that this VLP-epitope display platform is able to
induce potent antibody responses neutralizing GnRH in vivo and
protecting mice from lethal infection with influenza virus.
Moreover, the antibody response generated with AP205 VLPs is
largely comparable in magnitude and IgG-subtype pattern (Th1)
to what is obtained using RNA phage Qb (unpublished), whose
immunogenicity has been demonstrated in humans [22–24].
Remarkably, these AP205-VLPs were very receptive in
accepting foreign sequences, and self-assembled even when an
epitope with multiple cysteines such as the M2 epitope was fused
to the coat protein. The longest epitope we have fused so far to the
N-terminus of AP205 coat protein was 39 aa long, while to the C-
terminus it was 55 aa in length. Chemical peptide synthesis
becomes challenging with peptide length beyond 40 aa and this
new technology therefore widens the range of epitopes available
for vaccination. The ability to fuse to both ends of the AP205
VLP-subunit allows better display of N-or C- terminal epitopes
which is often difficult for other VLPs. Indeed, VLPs such as those
derived from the Hepatitis B core antigen (HBcAg), the
bacteriophage fr or filamentous phage particles only allow fusion
at one terminus of the subunit [37,38]. The availability of VLPs
suitable for fusing epitopes at either end is important, since for a
number of epitopes, the protective immune response raised, is
specific for their N- or C-terminal part (unpublished and [21]). In
addition, this will allow to more exhaustively test epitopes when
screening a whole pathogen genome or ‘‘antigenome’’ for
antigenicity as recently described [39].
A number of epitope-based vaccines targeting self-antigens are
in development targeting e.g. Ang II, GIP, Ab or GnRH [4]. We
have shown in this study that AP205 VLP fused to a self-antigen is
able to overcome B-cell unresponsiveness. In addition, the
antibodies neutralized their target, GnRH, as shown by testoster-
one level reduction and testis atrophy. An anti-GnRH vaccine
may find application as a therapeutic vaccine for prostate cancer.
Several vaccines are already in development for this indication.
Similarly, an influenza-pandemic vaccine with a rapid onset of
action is highly desirable. The M2 response we obtained is
remarkable, since not only was mortality avoided, but also
morbidity greatly reduced. Moreover, a 100% protection was
achieved even with the high dose of virus used in the challenge.
High antibody titres were already reached by day 14 in all
animals, demonstrating the rapid onset of the antibody response
when immunizing with AP205 RNA phage VLP. RNA bacterio-
phage VLPs are produced recombinantly in E. coli, achieving high
yield at a low cost of goods. An additional advantage of using
bacteria rather than eggs or eukaryotic cells for production is
speed. These features of the technology are highly relevant to the
design and production of vaccines for a pandemic. They are also
advantageous for the design of vaccines against emerging
pathogens or for biodefense applications.
Material and Methods
Cloning of coat protein fusions
Four intermediary plasmids for convenient subcloning of
fragments coding for epitopes by cassette mutagenesis were
prepared by PCR with pAP283 as template (Cielens et al.,
unpublished). Plasmids pAP378 and pAP382 were designed to
introduce epitopes with a short (GSGG), respectively a long amino
acid spacer (GSGTAGGGSGS) at the N-terminus, while plasmids
pAP409 and pAP405 were designed for introducing epitopes with
a short (GSG), respectively a long amino acid spacer (GTAG-
GGSG), at the C-terminus of AP205 coat protein. Oligodeox-
ynucleotide pairs were the following: p2.561 (59-TGCCATGG-
Figure 7. Protection of mice by immunization with M2-AP205
against a lethal influenza challenge. Mice were immunized on day
0 and 18 with M2-AP205 or AP205, and challenged with 46the lethal
dose of influenza Pr8 (H1N1) on day 31. (a) Anti-M2 and anti-AP205 IgG
titre on day 18 and 25 in mice immunized with M2-AP205. (b) Anti-
AP205 IgG titer on day 18 and 25 in mice immunized with AP205 only.
(c) Survival curve. 4 control animals had to be sacrificed on day 10 due
to excessive weight loss and temperature drop. Morbidity was assessed
by measurement of the animal weights (d) and temperature drop (e).
doi:10.1371/journal.pone.0009809.g007
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p1.46 (59-TGAAGCTTAAGCAGTAGTATCAGACGATACG-
39) for pAP378, p2.589 (59-TGCCATGGGTTCCGGAAC-
CGCGGGCGGGGGATCCGGTTCGGCAAATAA-GCCAA-
TGCAACC-39) and p1.46 (59-TGAAGCTTAAGCAGTAG-
TATCAGACGATACG-39) for pAP382, p1.45 (59-TGTCTA-
GAATTTTCTGCGCACCCATCCCGG-39) and p2.587 (59-
TGATGCATCCTCCGGATCCAGCAGTAGTATCAGACG-
ATAC-39) for pAP409 and p1.45 59-TGTCTAGAATTTTCTG-
CGCACCCATCCCGG-39) and p2.588 (59-TGATGCATAAT-
CCGGAACCGCCTCCTGCGGTTCCAGCAGTAGTATC-39)
for pAP405. The amplified fragments were subcloned into plasmid
pQb185 (pAP378 and pAP382) [40] or pQb10 (pAP409 and
pAP405) [41]. In pAP378 asparagine 14 is mutated to aspartate.
Fragments coding for epitopes to be fused at the N-terminus were
cloned as a NcoI-Kpn2I cassette, while constructs for fusion to the
C-terminus were cloned as a Kpn2I-Mph1103I cassette (Fig. 1). The
primer pairs for the plasmids coding an epitope fused to AP205
coat protein N- or C-terminus are described in the supplementary
Material and Methods (Text S1).
Expression and purification of AP205-fusion VLPs
Plasmids were transformed into E.coli JM109. A seed culture
was prepared by inoculating a single colony into LB medium
containing 20 mg/l Ampicillin and growing the culture overnight
at 37uC without shaking. For expression, the overnight culture was
diluted in M9 medium supplemented with casaminoacids (Difco)
and containing 20 mg/l Ampicillin and growth of the culture
carried out at 37uC with vigorous aeration for 14–20 hours.
Cells were resuspended in TEN buffer (20 mM Tris-HCl, 5mM
EDTA, 150 mM NaCl, pH 7.8) containing 1 mg/ml lysozyme
and 0.1% Tween 20, and lysed by three freeze thaw cycles
followed by ultrasonication. Clarified lysates were purified by one
or more sequential gel filtration steps using CL-4B, CL-2B and
Sepharose 6B columns (GE Healthcare). Some VLPs were
additionally purified by ultracentrifugation over a CsCl gradient.
Concentrations of the purified proteins were determined by the
Bradford test. For the AP205-GnRH vaccine, two bands reactive
with an anti-GnRH antiserum were observed when using vector
pAP405 for expression. This wasn’t observed in any other
construct. Subcloning into a pKK222 derivative however led to
a single band. The immunogenicity of both constructs was
equivalent.
Electron microscopy: Negative staining
Suspensions of VLPs were adsorbed on carbon-formvar coated
grids and stained with 1% phosphotungstic acid (pH 6.8). The
grids were examined with a JEM 100C electron microscope (Jeol
Ltd., Tokyo,Japan) at an accelerating voltage of 80 kV. Photo-
graphic records (negatives) were performed on Kodak electron
image film and electron micrographs were obtained by scanning of
negatives with EPSON 2480 PHOTO scanner.
Anti-peptide antibody response measured by ELISA
Peptides modified to contain a cysteine at their N- or C-termini,
and in some cases additionally a diglycine spacer, were conjugated
to ribonuclease A (RNAse) using the cross-linker SPDP (Pierce,
Rockford, IL, USA). The resulting conjugate was coated overnight
at 4uC on maxisorb plates (Nunc, Denmark), at a concentration of
10 mg/ml. Microtiter plates were blocked with 2% bovine serum
albumin in PBS supplemented with 0.05% Tween 20. Binding of
the sera was detected with a Horseradish-peroxidase goat anti-
mouse IgG conjugate. Binding of VLPs to anti-peptide sera was
assessed in an inhibition ELISA assay. Serial VLP dilutions were
pre-incubated with anti-peptide sera on blocked microtiter plates.
Remaining free antibody was detected by ELISA using an RNAse-
peptide conjugate as described above. The sera specific for Ang II
were raised using Ang II conjugated at its N-terminus to carrier
Qb.
Immunization of mice
Animal experiments were conducted according to guidelines set
by the Swiss Federal Veterinary Office (BVET) and were
approved by the Kantonale Veterina ¨ramt of Zu ¨rich. Balb/c mice
(n=3) were immunized subcutaneously on day 0 and 14 with
25 mg proteins of AP418, AP420, AP421 and AP422. The proteins
were diluted to a final volume of 200 ml in PBS, and 100 ml were
injected in the left and right inguinal region of each animal.
Animals were bled on day 14 and 21 for measurement of antibody
titre.
Anti-GnRH immunization
Male C57 BL/6 mice (n=5) were either immunized subcuta-
neously with 50 mg of AP205-GnRH on day 0 and 21, or
untreated (control animals). Animals were additionally bled on day
28 and 45, and were sacrificed on day 70. Testes were sampled,
weighed and testosterone was measured in serum.
Anti-M2 immunization and influenza challenge
C57BL/6 mice were kept in our animal facility, free of specific
pathogens. Influenza Virus PR8 (A/PuertoRico8/34, H1N1) was
originally provided by J. Pavlovic, University Zuerich. C57BL/6
mice (n=6) were immunized on day 0 and 18 with 50 mg of M2-
AP205 or AP205. On day 31, mice were infected intranasally (i.n.)
with 46LD50 (4610
4 p.f.u./ml) of PR8 virus (H1N1) in
endotoxin-free phosphate buffer saline (PBS) under isofluran
anaesthesia. Mice were monitored for another 22 days thereafter,
when body weight and rectal body temperature were determined
daily.
Supporting Information
Text S1 Supplementary Material and Methods.
Found at: doi:10.1371/journal.pone.0009809.s001 (0.04 MB
DOC)
Figure S1 Electron micrographs of AP205-D2 VLPs displaying
the D2 peptide. The D2 peptide was fused to the C-terminus
(AP418 - short linker, AP420 - long linker) or the N-terminus
(AP421 - short linker, AP422 - long linker) of AP205 coat protein.
Found at: doi:10.1371/journal.pone.0009809.s002 (5.78 MB TIF)
Figure S2 Coomassie-stained LDS-PAGE of AP205-D2 VLPs.
AP205 VLPs carrying D2 peptide fused to the C-terminus (AP418
and AP420) or N-terminus (AP421 and AP422) of AP205 coat
protein, analyzed by LDS PAGE. Lane 1 is the Marker, lane 2
AP205 VLP conjugated chemically to D2 peptide at an epitope
density of 1 peptide per AP205 subunit on average. The band
corresponding to one AP205 subunit fused to 1 D2 peptide is
marked by a star, the band corresponding to 2 peptides by two
stars, and the band corresponding to 3 peptides by 3 stars.
Found at: doi:10.1371/journal.pone.0009809.s003 (0.89 MB TIF)
Figure S3 Electron micrographs of chimeric AP205 VLPs
displaying longer foreign epitopes. Electron micrographs of
AP205 VLPs with Nef55 epitope fused to the C-terminus via
long linker (AP459), CXCR4 epitope fused to the N-terminus via
short linker (AP543), and M2 epitope fused to the N-terminus via
short linker (AP551).
Found at: doi:10.1371/journal.pone.0009809.s004 (3.14 MB TIF)
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